Search

Your search keyword '"Harata-Lee, Yuka"' showing total 29 results
Start Over Author "Harata-Lee, Yuka"
29 results on '"Harata-Lee, Yuka"'

7. Corrigendum to “Future directions for the discovery of natural product-derived immunomodulating drugs: An IUPHAR positional review” [Pharmacol. Res. 177 (2022) 106076]

Author

Wainwright, Cherry L., primary, Teixeira, Mauro M., additional, Adelson, David L., additional, Buenz, Eric J., additional, David, Bruno, additional, Glaser, Keith B., additional, Harata-Lee, Yuka, additional, Howes, Melanie-Jayne R., additional, Izzo, Angelo A., additional, Maffia, Pasquale, additional, Mayer, Alejandro M.S., additional, Mazars, Claire, additional, Newman, David J., additional, Lughadha, Eimear Nic, additional, Pimenta, Adriano M.C., additional, Parra, John A.A., additional, Qu, Zhipeng, additional, Shen, Hanyuan, additional, Spedding, Michael, additional, and Wolfender, Jean-Luc, additional

Published
2022
Full Text
View/download PDF

8. Future directions for the discovery of natural product-derived immunomodulating drugs

Author

Wainwright, Cherry L., Teixeira, Mauro M., Adelson, David L., Buenz, Eric J., David, Bruno, Glaser, Keith B., Harata-Lee, Yuka, Howes, Melanie-Jayne R., Izzo, Angelo A., Maffia, Pasquale, Mayer, Alejandro M.S., Mazars, Claire, Newman, David J., Nic Lughadha, Eimear, Pimenta, Adriano M.C., Parra, John A.A., Qu, Zhipeng, Shen, Hanyan, Spedding, Michael, and Wolfender, Jean-Luc

Abstract

Drug discovery from natural sources is going through a renaissance, having spent many decades in the shadow of synthetic molecule drug discovery, despite the fact that natural product-derived compounds occupy a much greater chemical space than those created through synthetic chemistry methods. With this new era comes new possibilities, not least the novel targets that have emerged in recent times and the development of state-of-the-art technologies that can be applied to drug discovery from natural sources. Although progress has been made with some immunomodulating drugs, there remains a pressing need for new agents that can be used to treat the wide variety of conditions that arise from disruption, or over-activation, of the immune system; natural products may therefore be key in filling this gap. Recognising that, at present, there is no authoritative article that details the current state-of-the-art of the immunomodulatory activity of natural products, this in-depth review has arisen from a joint effort between the International Union of Basic and Clinical Pharmacology (IUPHAR) Natural Products and Immunopharmacology, with contributions from a Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation number of world-leading researchers in the field of natural product drug discovery, to provide a “position statement” on what natural products has to offer in the search for new immunomodulatory argents. To this end, we provide a historical look at previous discoveries of naturally occurring immunomodulators, present a picture of the current status of the field and provide insight into the future opportunities and challenges for the discovery of new drugs to treat immune-related diseases.

Published
2022

11. Regulation of chemotactic networks by 'atypical' receptors

Author

Comerford, Iain, Litchfield, Wendel, Harata-lee, Yuka, Nibbs, Robert J.B., and McColl, Shaun R.

Subjects
Cell migration -- Research, Chemokines -- Research, Human genetics -- Research, Transduction -- Research, Biological sciences
Abstract

'Atypical' receptors play a role in scavenging, or altering the localization of, chemoattractant molecules through binding and/or internalizing their ligands without activating signal transduction cascades leading to cell migration. The evidence that these receptors play a role in regulating cell migration is discussed, and their therapeutic potential in human diseases is also analyzed.

Published
2007

13. ACKR4 restrains antitumor immunity by regulating CCL21

Author

Whyte, Carly E., primary, Osman, Maleika, additional, Kara, Ervin E., additional, Abbott, Caitlin, additional, Foeng, Jade, additional, McKenzie, Duncan R., additional, Fenix, Kevin A., additional, Harata-Lee, Yuka, additional, Foyle, Kerrie L., additional, Boyle, Sarah T., additional, Kochetkova, Marina, additional, Aguilera, Amelia Roman, additional, Hou, Jiajie, additional, Li, Xian-Yang, additional, Armstrong, Mark A., additional, Pederson, Stephen M., additional, Comerford, Iain, additional, Smyth, Mark J., additional, and McColl, Shaun R., additional

Published
2020
Full Text
View/download PDF

19. Multiple functions of CXCL12 in a syngeneic model of breast cancer

Author

Smyth Mark J, Anderson Robin L, Comerford Iain, Harata-Lee Yuka, Williams Sharon A, and McColl Shaun R

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background A growing body of work implicates chemokines, in particular CXCL12 and its receptors, in the progression and site-specific metastasis of various cancers, including breast cancer. Various agents have been used to block the CXCL12-CXCR4 interaction as a means of inhibiting cancer metastasis. However, as a potent chemotactic factor for leukocytes, CXCL12 also has the potential to enhance anti-cancer immunity. To further elucidate its role in breast cancer progression, CXCL12 and its antagonist CXCL12(P2G) were overexpressed in the syngeneic 4T1.2 mouse model of breast carcinoma. Results While expression of CXCL12(P2G) significantly inhibited metastasis, expression of wild-type CXCL12 potently inhibited both metastasis and primary tumor growth. The effects of wild-type CXCL12 were attributed to an immune response characterized by the induction of CD8+ T cell activity, enhanced cell-mediated cytotoxicity, increased numbers of CD11c+ cells in the tumor-draining lymph nodes and reduced accumulation of myeloid-derived suppressor cells in the spleen. Conclusions This study highlights the need to consider carefully therapeutic strategies that block CXCL12 signaling. Therapies that boost CXCL12 levels at the primary tumor site may prove more effective in the treatment of metastatic breast cancer.

Published
2010
Full Text
View/download PDF

28. An immune paradox: How can the same chemokine axis regulate both immune tolerance and activation?

Author

Comefford, Iain, Bunting, Mark, Fenix, Kevin, Haylock-Jacobs, Sarah, Litchfield, Wendel, Harata-Lee, Yuka, Turvey, Michelle, Brazzatti, Jufie, Gregor, Carly, Nguyen, Phillip, Kara, Ervin, and McColl, Shaun R.

Subjects
AUTOIMMUNITY, CHEMOKINES, LIGANDS (Biochemistry), IMMUNOLOGICAL tolerance, AUTOIMMUNE diseases, T cells
Abstract

The article discusses the function of chemokine receptor 6/CC-chemokine ligand 20 (CCR6/CCL20) in the regulation of immune tolerance and inflammation in cases of autoimmune diseases. It states that targeting CCR6/CCL20, is known to follow the same chemokine pathway due to shared evolutionary development. The authors add that pathway of CCR6/CCL20 involves the recruitment of suppressive and pro-inflammatory T cell subsets which could be useful in the treatment of human diseases.

Published
2010
Full Text
View/download PDF

29. ACKR4 restrains antitumor immunity by regulating CCL21

Author

Marina Kochetkova, Mark A. Armstrong, Caitlin Abbott, Kerrie L Foyle, Ervin E. Kara, Kevin A. Fenix, Jade Foeng, Jiajie Hou, Yuka Harata-Lee, Maleika Osman, Stephen Pederson, Sarah T. Boyle, Carly E. Whyte, Shaun R. McColl, Duncan R. McKenzie, Xian-Yang Li, Amelia Roman Aguilera, Mark J. Smyth, Iain Comerford, Whyte, Carly E, Osman, Maleika, Kara, Ervin E, Abbott, Caitlin, Foeng, Jade, McKenzie, Duncan R, Fenix, Kevin A, Harata-Lee, Yuka, Foyle, Kerrie L, Boyle, Sarah T, Kochetkova, Marina, Aguilera, Amelia Roman, Hou, Jian, Li, Xian-Yang, Armstrong, Mark A, Pederson, Stephen M, Comerford, Iain, Smyth, Mark J, and McColl, Shaun R

Subjects
endocrine system, medicine.medical_treatment, T cell, Immunology, CD8-Positive T-Lymphocytes, Receptors, CCR, T-cell, Antigens, CD, Neoplasms, medicine, Immunology and Allergy, Animals, Humans, tumor microenvironment (TME), Neoplasm Metastasis, Solid Tumors, Immune Checkpoint Inhibitors, Cell Proliferation, Tumor microenvironment, Chemokine CCL21, Chemistry, Cell growth, Immunity, Brief Definitive Report, Immunotherapy, Dendritic cell, Dendritic Cells, Survival Analysis, Immune checkpoint, Mice, Inbred C57BL, Disease Models, Animal, medicine.anatomical_structure, tumor specific T cells, Cancer research, Stromal Cells, Integrin alpha Chains, CD8, CCL21
Abstract

Whyte et al. demonstrate that regulation of intratumor CCL21 and DC trafficking from tumors by the atypical chemokine receptor 4 curtails intratumor CD8+ T cell accumulation and immunotherapy efficacy., Current immunotherapies involving CD8+ T cell responses show remarkable promise, but their efficacy in many solid tumors is limited, in part due to the low frequency of tumor-specific T cells in the tumor microenvironment (TME). Here, we identified a role for host atypical chemokine receptor 4 (ACKR4) in controlling intratumor T cell accumulation and activation. In the absence of ACKR4, an increase in intratumor CD8+ T cells inhibited tumor growth, and nonhematopoietic ACKR4 expression was critical. We show that ACKR4 inhibited CD103+ dendritic cell retention in tumors through regulation of the intratumor abundance of CCL21. In addition, preclinical studies indicate that ACKR4 and CCL21 are potential therapeutic targets to enhance responsiveness to immune checkpoint blockade or T cell costimulation.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results